Human Milk Oligosaccharides Market Size, Share & Forecast 2026-2033

Overview

The Global Human Milk Oligosaccharides Market size was valued at USD 549.7 million in 2025 and is expected to reach USD 1,753.3 million by 2033, growing with a CAGR of 15.6% during the forecast period 2026-2033. The growth in the infant population is a major driver of the human milk oligosaccharides (HMOs) market, as increasing birth rates sustain demand for infant nutrition products that closely replicate the health benefits of human breast milk.

HMOs are the third most abundant solid component in breast milk and play a vital role in supporting infant gut microbiota, immune system development, and protection against pathogens. As more parents seek scientifically formulated infant formulas that mimic the composition of breast milk, manufacturers are increasingly incorporating HMOs into premium infant nutrition market, driving market expansion.

Global birth trends continue to provide a strong foundation for this demand. According to Our World in Data's Fertility Rate Dataset, the global fertility rate is projected to reach 2.1961 births per woman by 2030. Additionally, the United Nations estimates that approximately 250 infants are born every minute worldwide, translating to more than 130 million births annually, or roughly 353,000 births each day. This consistently large infant population creates sustained demand for infant formula market and early-life nutrition products enriched with HMOs, encouraging manufacturers to expand production capacity, invest in HMO innovation, and introduce advanced nutritional formulations, thereby driving the growth of the global human milk oligosaccharides market.

Drivers

Increasing Emphasis on Gut Health

The increasing emphasis on gut health is a key driver of the human milk oligosaccharide (HMO) market as consumers become more aware of the importance of maintaining a healthy gut microbiome for overall well-being. HMOs are recognized as highly effective prebiotics that selectively nourish beneficial bacteria such as Bifidobacteria, helping to improve microbial balance, strengthen the intestinal barrier, and enhance digestive health. Growing interest in preventive healthcare and functional nutrition has expanded the use of HMOs beyond infant nutrition into dietary supplements and functional foods targeted at adults seeking digestive and immune health benefits.

Consumer experiences and growing scientific interest are further supporting market expansion. According to a September 2024 survey by Layer Origin Nutrition, HMOs help nourish beneficial gut bacteria, increase the production of beneficial short-chain fatty acids such as butyrate, and support overall gut health. Among 134 PureHMO users, participants reported improvements in symptoms including bloating, constipation, diarrhea, abdominal pain, brain fog, fatigue, and skin issues, suggesting that HMO supplementation may offer benefits beyond digestion and contribute to broader health and wellness. While these findings are based on self-reported survey data and should be interpreted alongside controlled clinical evidence, they reflect rising consumer confidence in HMOs as functional ingredients, driving demand and growth in the human milk oligosaccharide market.

Increasing R&D Activities

Increasing R&D activities are playing a crucial role in driving the growth of the human milk oligosaccharides (HMOs) market by expanding scientific understanding of HMOs and uncovering new health applications beyond infant nutrition. Research is increasingly demonstrating the role of HMOs in supporting gut microbiota, immune function, metabolic health, and overall well-being, encouraging manufacturers to develop innovative products for infants, children, and adults. Advances in biotechnology and microbiome science are also enabling the discovery of new HMO structures and improving production methods, making these bioactive ingredients more accessible for use in functional foods, dietary supplements, and specialized nutrition products.

Collaborative research initiatives are further accelerating market development. In March 2024, the University of California San Diego and Novonesis established a leading research consortium to advance HMO science and promote the development of synbiotics, which combine HMOs with probiotics to support a balanced gut microbiome, digestion, and immune health. Similarly, in January 2024, Kyowa Hakko Bio partnered with Singapore’s Agency for Science, Technology and Research (A*STAR) to investigate the broader health benefits of HMOs, including their roles in immune regulation and gut microbiome health throughout different stages of life. These ongoing R&D efforts are driving innovation, expanding clinical evidence, and creating new commercial opportunities, thereby fueling the growth of the global HMOs market.

Pricing Premiumization of HMO-Enriched Infant Nutrition

Pricing premiumization is emerging as a key growth enabler in the human milk oligosaccharides (HMOs) market, as manufacturers position HMO-enriched infant formulas at a significant price premium compared to conventional formulations. HMOs are considered advanced bioactive ingredients with clinically supported benefits related to gut microbiota development and immune system support, allowing brands to differentiate products in the high-end infant nutrition segment.

This premium positioning is particularly evident in developed markets, where consumers demonstrate a willingness to pay higher prices for scientifically advanced formulas that closely replicate human breast milk. As a result, HMOs are increasingly integrated into “gold standard” infant nutrition products, enabling manufacturers to improve margin structures while offsetting high production costs associated with precision fermentation. Over time, improving manufacturing efficiency is expected to gradually reduce cost barriers, but pricing differentiation is likely to remain a key feature of the market.

Restraint

Regulatory Approvals

Regulatory approvals are a significant restraint on the growth of the human milk oligosaccharides (HMOs) market because HMOs are novel bioactive ingredients that must undergo rigorous safety, quality, and efficacy evaluations before they can be approved for use in infant formula, dietary supplements, and functional foods. Regulatory authorities in different countries have varying approval pathways and labeling requirements, requiring manufacturers to generate extensive toxicological, clinical, and manufacturing data. These lengthy and complex approval processes increase development costs, delay product commercialization, and create challenges for companies seeking to launch HMO-based products across multiple international markets.

The regulatory landscape is further complicated by differences in permitted HMO types, allowable health claims, and ingredient specifications across regions. While certain HMOs have received approval in markets such as the United States and Europe, many emerging economies are still developing their regulatory frameworks for these ingredients. As a result, manufacturers must navigate multiple country-specific compliance requirements, which can slow market expansion and limit the availability of innovative HMO formulations. These regulatory hurdles are particularly challenging for smaller companies with limited resources, making regulatory approvals a key restraint on the overall growth of the human milk oligosaccharides market.

Human Milk Oligosaccharides Market Trends & Opportunities

Advancements in Precision Fermentation and Biotechnology

Advancements in precision fermentation and biotechnology are a key trend in the human milk oligosaccharides (hmos) market report, enabling the scalable, cost-effective, and high-purity production of complex HMOs that closely replicate those found in human breast milk. These technologies are expanding the range of commercially available HMO structures and facilitating the development of next-generation nutritional products with enhanced functional benefits. A notable example is dsm-firmenich’s partnership with Lallemand Health Solutions in April 2024, which focused on developing synbiotic solutions by combining precision-fermentation-derived HMOs with probiotics to better mimic the gut microbiome of breastfed infants. During 2024, dsm-firmenich also secured additional regulatory approvals for HMOs in the UK and European Union while expanding its HMO portfolio, demonstrating how advances in biotechnology are accelerating product innovation, broadening market access, and supporting the growing adoption of HMOs across infant nutrition and broader health applications.

Strategic Partnerships

Strategic partnerships are an emerging trend in the human milk oligosaccharides (HMOs) market as companies collaborate to combine expertise in biotechnology, manufacturing, and commercialization to accelerate product development and expand global market reach. These partnerships enable manufacturers to scale production using advanced precision fermentation technologies while improving supply chain efficiency and regulatory access for HMO-based ingredients. A notable example is the June 2025 partnership between BENEO and WACKER, under which WACKER leverages its expertise in precision fermentation to produce the HMO 2′-Fucosyllactose (2′-FL), while BENEO leads global commercialization. The collaboration has already begun supplying 2′-FL to European infant formula manufacturers, demonstrating how strategic alliances are facilitating faster market penetration, expanding HMO availability, and supporting innovation in infant nutrition and functional health products.

Hospital and Clinical Procurement Adoption

Hospitals and maternity care institutions are emerging as an important early adoption channel for HMO-enriched infant formulas, particularly in neonatal intensive care units (NICUs) and postnatal care settings. Healthcare professionals increasingly recommend specialized formulas containing HMOs due to their structural similarity to breast milk oligosaccharides and their potential role in supporting immune development and gut microbiome establishment in early infancy.

This institutional adoption is reinforcing clinical credibility for HMOs and accelerating trust among parents during early feeding decisions. In several developed healthcare systems, hospital discharge recommendations significantly influence long-term infant formula brand selection, making clinical procurement pathways an important commercialization channel for HMO manufacturers. As clinical evidence continues to expand, hospital-based adoption is expected to play a larger role in shaping premium infant nutrition demand.

Segment Analysis

The global human milk oligosaccharides industry is segmented based on type, concentration, application and region.

2′-FL Held the Largest Market Share

2′-FL market segment held the largets market revenue share of more than 45% in the year 2025. The 2′-Fucosyllactose (2′-FL) segment is growing in the human milk oligosaccharides (HMOs) market because it is one of the most abundant and extensively researched HMOs found in human breast milk. Numerous scientific studies have demonstrated its ability to promote the growth of beneficial gut bacteria, particularly Bifidobacteria, strengthen immune function, and support healthy gastrointestinal development in infants. As manufacturers increasingly seek to formulate infant nutrition products that more closely resemble the composition and functional benefits of human milk, demand for 2′-FL continues to rise. Its well-established safety profile and expanding use in infant formula, dietary supplements, and fnctional nutrition products are further driving segment growth.

Regulatory progress is also supporting wider commercialization of 2′-FL across global markets. In May 2024, the Center for Food Safety Assessment (CFSA) issued a draft and reopened the public consultation period for 2′-FL and Lacto-N-neotetraose (LNnT), reflecting continued regulatory evaluation and potential expansion of approved HMO ingredients. Such developments are expected to facilitate broader market access and encourage manufacturers to incorporate 2′-FL into a wider range of nutritional products. As regulatory acceptance expands alongside growing clinical evidence, the 2′-FL segment is expected to maintain its leading position within the global human milk oligosaccharides market.

Increasing Demand to Replicate the Nutritional Composition and Functional Benefits of Human Breast Milk

The infant formula market segment is growing in the human milk oligosaccharides (HMOs) market as manufacturers increasingly develop premium formulas that more closely replicate the nutritional composition and functional benefits of human breast milk. HMOs play a critical role in supporting infant gut microbiota, immune system development, and digestive health, making them a key differentiating ingredient in next-generation infant nutrition products. Rising parental awareness of early-life nutrition, combined with increasing demand for scientifically formulated premium infant formulas, is driving the incorporation of multiple HMO structures into commercial products, thereby fueling segment growth.

Product innovation and geographic expansion by leading infant nutrition companies are further accelerating market adoption. In June 2025, Nestlé expanded its NAN Sinergity infant formula range into Latin America, the Middle East, and Asia. Positioned as a premium nutrition platform, the product features an advanced blend of six Human Milk Oligosaccharides (HMOs) that are structurally identical to those found in breast milk, combined with the probiotic Bifidobacterium infantis. This combination is designed to better support gut microbiome development and immune health in infants, highlighting the growing industry focus on advanced HMO-enriched formulations and driving continued growth of the infant formula segment.

Functional Food & Beverages Market Segment is the Fastest Growing in the HMOs Market

The functional food & beverages market segment is the fastest growing in the HMOs market as consumers increasingly seek foods and beverages that provide scientifically backed health benefits beyond basic nutrition. HMOs are gaining recognition for their prebiotic properties, which help support a healthy gut microbiome, digestive health, and immune function. This growing interest in preventive healthcare and functional nutrition is encouraging manufacturers to incorporate HMOs into a wider range of products, including fortified foods, nutritional beverages, and specialized dietary formulations for infants and adults, thereby expanding the segment's growth potential.

Regulatory approvals are further accelerating the adoption of HMOs in functional food applications. In September 2024, Kyowa Hakko Bio received approval from India’s Food Safety and Standards Authority (FSSAI) for the use of 2′-Fucosyllactose (2′-FL) as a food ingredient, enabling its incorporation into infant nutrition products in the Indian market. This approval not only expands commercial opportunities in one of the world's largest consumer markets but also strengthens confidence in the safety and efficacy of HMOs as functional ingredients. As regulatory acceptance broadens globally, manufacturers are expected to introduce more HMO-enriched food and beverage products, driving continued growth of the Functional Food & Beverages segment.

Geographical Penetration

North America Human Milk Oligosaccharides Market: Driven by Strong Regulatory Support

The Human Milk Oligosaccharides (HMOs) market in North America is growing due to strong regulatory support for innovation in infant nutrition, increasing demand for premium infant formulas, and expanding clinical evidence demonstrating the health benefits of HMOs. Parents are increasingly seeking formulas that more closely resemble human breast milk, driving manufacturers to incorporate multiple HMOs into advanced nutritional products. At the same time, favorable regulatory initiatives are encouraging product development and strengthening the resilience of the infant formula supply chain, creating a supportive environment for HMO adoption.

This trend is reflected in recent industry and regulatory developments. In January 2025, the U.S. Food and Drug Administration (FDA) introduced its Long-Term National Strategy, followed by the launch of Operation Stork Speed in March 2025, both aimed at improving infant formula quality, strengthening supply resilience, and encouraging the development of innovative infant nutrition products. Complementing these efforts, Abbott presented new 2024 clinical data showing that Similac 360 Total Care, formulated with five HMOs, supports gut health, immune function, brain development, and growth comparable to that of breastfed infants. Together, these developments are reinforcing confidence in HMO-enriched formulas and driving sustained growth of the human milk oligosaccharides market across North America.

Europe Human Milk Oligosaccharides Market: Driven by the Commercialization of Advanced Bioactive Ingredients

The Human Milk Oligosaccharides (HMOs) market in Europe is growing due to increasing innovation in infant nutrition and strong regulatory support that enables the commercialization of advanced bioactive ingredients. European consumers are highly focused on scientifically backed, high-quality infant formulas that closely replicate the benefits of breast milk, driving demand for HMOs that support gut health, immunity, and overall infant development. At the same time, ongoing research and product development are accelerating the integration of HMOs into next-generation nutritional solutions across the region.

This growth is further reinforced by industry collaboration and regulatory expansion. In April 2024, dsm-firmenich partnered with Lallemand Health Solutions to develop synbiotic products combining HMOs and probiotics, designed to better replicate the microbiome of breastfed infants and enhance gut health benefits. Additionally, the company expanded its HMO regulatory approvals across Europe during 2024, enabling broader commercialization and adoption in infant formula and functional nutrition products. These developments are strengthening Europe’s position as a key innovation hub for HMOs and driving sustained market growth.

Asia-Pacific Human Milk Oligosaccharides Market: Driven by the Infant Population Base

Asia-Pacific is the largest and the fastest growing region due to a large and sustained infant population base, rising awareness of early-life nutrition, and increasing demand for premium infant formula products that closely replicate breast milk. Parents across the region are becoming more health-conscious and are actively seeking scientifically advanced nutrition solutions that support gut health, immunity, and cognitive development in infants. This is encouraging infant formula manufacturers to incorporate HMOs as key functional ingredients, driving strong market expansion across major Asia-Pacific economies.

Market growth is further supported by both demographic strength and expanding scientific research in the region. According to BBC data, China recorded 7.92 million births in 2025, highlighting continued large-scale demand for infant nutrition products, including HMO-enriched formulas. Additionally, in January 2024, Kyowa Hakko Bio partnered with the Singapore Institute for Clinical Sciences (SICS) to advance research on HMOs, focusing on their role in immune regulation and gut microbiome health across different life stages. Such collaborations are strengthening regional R&D capabilities, improving scientific understanding of HMOs, and supporting innovation in functional nutrition, all of which are contributing to the rapid growth of the Asia-Pacific HMOs market.

South America Human Milk Oligosaccharides Market: Driven by Increasing Adoption of Premium Infant Formula

The Human Milk Oligosaccharides (HMOs) market in South America is growing due to rising awareness of infant nutrition, increasing adoption of premium infant formula, and gradual improvements in healthcare and nutritional standards across the region. As parents become more informed about the importance of gut health, immunity, and early-life development, there is growing demand for scientifically advanced formulas that more closely resemble human breast milk, encouraging manufacturers to introduce HMO-enriched products in emerging Latin American markets.

Market expansion is also being supported by increasing penetration of global infant nutrition companies and wider availability of fortified products in retail and pharmacy channels. Multinational players are expanding distribution networks and launching premium formulations containing HMOs to meet evolving consumer expectations in countries such as Brazil, Mexico, and Argentina. In addition, rising urbanization, improving disposable incomes, and a growing middle class are further driving demand for high-quality infant nutrition, collectively supporting the steady growth of the HMOs market in South America.

Middle East & Africa Human Milk Oligosaccharides Market: Driven by Increasing Birth Rates in Several Countries

The Human Milk Oligosaccharides (HMOs) market in the Middle East & Africa is growing due to rising awareness of infant health and nutrition, increasing birth rates in several countries, and expanding demand for premium and scientifically advanced infant formula products. Parents in urban areas are becoming more conscious of early-life nutrition, particularly the importance of gut health, immunity, and cognitive development, which is driving adoption of HMO-enriched formulas that mimic the benefits of breast milk. As healthcare infrastructure improves and access to modern nutritional products expands, manufacturers are increasingly introducing premium infant formula offerings containing HMOs across retail and pharmacy channels.

Market growth is further supported by the gradual expansion of multinational infant nutrition companies and improving distribution networks across the region. Rising disposable incomes in parts of the Middle East, along with increasing urbanization in African economies, are contributing to higher demand for high-quality infant nutrition products. In addition, growing exposure to global nutrition trends and increased awareness campaigns by healthcare professionals are encouraging caregivers to choose advanced formula products with functional ingredients like HMOs, thereby supporting steady market expansion across the Middle East & Africa.

Key Developments

·         In March 2026, dsm-firmenich strengthens HMO offering in Asia with new regulatory approvals. The company continues its regulatory success in Asia’s early life nutrition market with approval of four new HMOs in Malaysia and Thailand alongside commercial authorization of its 3’-SL ingredient in China.

·         In February 2026, Meihua Group, supported by CIRS Group, obtained the first approval for 3'-SL in China. CIRS Group stated that the approval is a significant milestone for compliant HMO ingredients in the country.

·      In April 2025, dsm-firmenich, has announced the approval of its human milk oligosaccharide (HMO), 2'-O-Fucosyllactose (2'-FL)—commercially known as GLYCARE® 2FL—as a functional ingredient for early life nutrition in India. This regulatory milestone marks a new opportunity to enhance infant health, as well as support HMO innovation in the region, with GLYCARE® 2FL representing dsm-firmenich’s first HMO approval in India.